EP Patent

EP4101454A1 — Compositions for use in the treatment of hypertension

Assigned to George Institute for Global Health · Expires 2022-12-14 · 3y expired

What this patent protects

Provided herein are pharmaceutical compositions for use in treating hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker, more particularly a composition for such use comprising telmisartan, indapamide and amlodipine besylate.

USPTO Abstract

Provided herein are pharmaceutical compositions for use in treating hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker, more particularly a composition for such use comprising telmisartan, indapamide and amlodipine besylate.

Drugs covered by this patent

Patent Metadata

Patent number
EP4101454A1
Jurisdiction
EP
Classification
—
Expires
2022-12-14
Drug substance claim
No
Drug product claim
No
Assignee
George Institute for Global Health
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.